The integrated platform of Protéus has been designed to enable the company's industrial partner to accelerate the time-to-market of their new products. This platform combines a unique collection of biodiversity with proprietary technologies for functional high througput screening, directed evolution and assessment of the immunogenicity of proteins.
Protéus' clients also benefits from the company's in house protein production and formulation expertise and capabilities, which makes Protéus a leading company in the design and development of novel proteins.
In order to constantly expand its platform and strengthen its technological leadership, Protéus has created a network of exclusive collaborations with internationally renowned scientists.
Recently, our collaboration with the Life Science Department of CEA, the French governmental agency for nuclear energy, has resulted into the addition of key technologies and capabilities for the in vitro experimental assessment of the immunogenicity of proteins on human immunologic systems.